Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment.
Anticancer drugs
Assessment algorithm
Complementary medicine
Herb-drug interactions
Herbal supplements
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
13
03
2019
accepted:
23
05
2019
pubmed:
4
6
2019
medline:
17
1
2020
entrez:
3
6
2019
Statut:
ppublish
Résumé
To develop a system to estimate the risk of herb-drug interactions that includes the available evidence from clinical and laboratory studies, transparently delineates the algorithm for the risk estimation, could be used in practice settings and allows for adaptation and update. We systematically searched Drugbank, Transformer, Drug Information Handbook, European and German Pharmacopoeia and MEDLINE for studies on herb-drug interactions of five common medicinal plants (coneflower, ginseng, milk thistle, mistletoe and St. John's wort). A diverse set of data were independently extracted by two researchers and subsequently analysed by a newly developed algorithm. Results are displayed in the form of interaction risk categories. The development of the algorithm was guided by an expert panel consensus process. From 882 publications retrieved by the search, 154 studies were eligible and provided 529 data sets on herbal interactions. The developed algorithm prioritises results from clinical trials over case reports over in vitro investigations and considers type of study, consistency of study results and study outcome for clinical trials as well as identification, permeability, bioavailability, and interaction potency of an identified herbal perpetrator for in vitro investigations. Risk categories were assigned to and dynamically visualised in a colour-coded matrix format. The novel algorithm allows to transparently generate and dynamically display herb-drug interaction risks based on the available evidence from clinical and laboratory pharmacologic studies. It provides health professionals with readily available and easy updatable information about the risk of pharmacokinetic interactions between herbs and oncologic drugs.
Identifiants
pubmed: 31154477
doi: 10.1007/s00228-019-02700-6
pii: 10.1007/s00228-019-02700-6
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1237-1248Subventions
Organisme : Deutsche Krebshilfe
ID : 110150
Références
Br J Clin Pharmacol. 2001 Nov;52(5):587-95
pubmed: 11736868
Pharmacotherapy. 2002 May;22(5):551-6
pubmed: 12013352
Phytother Res. 2002 Nov;16(7):632-8
pubmed: 12410543
Pharmacol Toxicol. 2002 Nov;91(5):209-17
pubmed: 12570028
J Clin Pharmacol. 2003 May;43(5):443-69
pubmed: 12751267
Am J Ther. 2003 May-Jun;10(3):163-9
pubmed: 12756423
Pharmacotherapy. 2003 Jul;23(7):866-70
pubmed: 12885100
Support Care Cancer. 2004 Jun;12(6):454-62
pubmed: 14991387
Patient Educ Couns. 2004 Apr;53(1):5-11
pubmed: 15062898
Drug Metab Dispos. 2004 Jun;32(6):587-94
pubmed: 15155549
Clin Pharmacol Ther. 2004 Nov;76(5):428-40
pubmed: 15536458
Eur J Clin Pharmacol. 2005 Mar;61(1):1-7
pubmed: 15666173
Ann Oncol. 2005 Apr;16(4):655-63
pubmed: 15699021
Ann Pharmacother. 2005 Jun;39(6):1064-72
pubmed: 15886285
Drug Metab Dispos. 2006 Jan;34(1):69-74
pubmed: 16221754
Drug Saf. 2005;28(12):1131-9
pubmed: 16329715
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72
pubmed: 16381955
Life Sci. 2006 Mar 27;78(18):2105-15
pubmed: 16427092
Br J Clin Pharmacol. 2007 Mar;63(3):258-67
pubmed: 17116126
Clin Pharmacol Ther. 2007 Feb;81(2):298-304
pubmed: 17259955
Drug Metab Dispos. 2007 Nov;35(11):2035-9
pubmed: 17670841
Planta Med. 2007 Nov;73(14):1429-35
pubmed: 17968815
Support Care Cancer. 2010 Jul;18(7):883-91
pubmed: 19756775
Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43
pubmed: 19934256
Br J Cancer. 2011 Mar 15;104(6):927-33
pubmed: 21364591
BMC Complement Altern Med. 2011 Apr 15;11:30
pubmed: 21496245
Cancer. 2011 Nov 15;117(22):5142-50
pubmed: 21538342
Integr Cancer Ther. 2012 Sep;11(3):187-203
pubmed: 22019489
J Altern Complement Med. 2012 Feb;18(2):165-74
pubmed: 22320169
Planta Med. 2012 Sep;78(13):1421-7
pubmed: 22814819
Clin Pharmacol Ther. 2014 Feb;95(2):189-98
pubmed: 24048277
Clin Pharmacol Ther. 2014 Feb;95(2):133-5
pubmed: 24448459
Clin Pharmacol Ther. 2014 Apr;95(4):354-5
pubmed: 24646483
Lancet Oncol. 2014 Jul;15(8):e315-26
pubmed: 24988935
Drug Metab Dispos. 2014 Oct;42(10):1611-6
pubmed: 25028567
Br J Clin Pharmacol. 2015 Feb;79(2):241-53
pubmed: 25125025
J Ethnopharmacol. 2015 Apr 2;163:149-56
pubmed: 25623616
Drug Metab Dispos. 2016 Feb;44(2):162-71
pubmed: 26438626
Med Ref Serv Q. 2015;34(4):461-70
pubmed: 26496400
Regul Toxicol Pharmacol. 2016 Apr;76:1-6
pubmed: 26776752
CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):701-10
pubmed: 26904384
Med Oncol. 2016 May;33(5):52
pubmed: 27090799